Troels Koch

Senior Vice President

MINA Therapeutics


Troels Koch (TK) has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche – and Exiqon A/S was in 2016 acquired by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has positioned LNA antisense science and technology at an international lead position. TK has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held >100 invited presentations at international conferences and is author of 85 peer reviewed publications. TK has since 2020 worked as an independent consultant in RNA therapeutics and oligonucleotide science and is engaged in serial biotech company building.